Theraclion SA (FR:ALTHE)
:ALTHE
Top Page
Theraclion SA
(ALTHE)
Select Model
Select Model
Rating:46Neutral
Price Target:
€0.65
▲(6.07% Upside)
Action:ReiteratedDate:01/31/26
The score is weighed down primarily by very weak financial performance (sharp revenue decline, sustained losses, and negative equity/solvency concerns). Technicals are neutral-to-slightly constructive, offering limited support, while valuation remains unattractive due to negative earnings and no dividend yield data.
Positive Factors
Focused HIFU non‑invasive therapy
Theraclion's specialization in high‑intensity focused ultrasound (HIFU) and ultrasound-based therapy for outpatient indications is a durable competitive strength. A narrow, proprietary technology focus can support differentiated products, clinical adoption, and specialized sales channels over multiple quarters.
Negative Factors
Severe recent revenue decline
A roughly 75% revenue collapse materially weakens scale economics and undermines the business's ability to fund R&D, sales, and regulatory efforts. Sustained top‑line erosion makes margin recovery harder, increases dependency on external capital, and can erode market share over multiple reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused HIFU non‑invasive therapy
Theraclion's specialization in high‑intensity focused ultrasound (HIFU) and ultrasound-based therapy for outpatient indications is a durable competitive strength. A narrow, proprietary technology focus can support differentiated products, clinical adoption, and specialized sales channels over multiple quarters.
Read all positive factors
Theraclion SA (ALTHE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€27.44M
Dividend YieldN/A
Average Volume (3M)82.89K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-4.70%
EPS Growth-64.31%
CountryFR
Employees28
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding59,819,260
10 Day Avg. Volume39,747
30 Day Avg. Volume82,891
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-133.83K
Price to Sales (P/S)18.38
P/FCF Ratio-5.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Theraclion SA Business Overview & Revenue Model
Company Description
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echoth...
How the Company Makes Money
Theraclion generates revenue primarily through the sale of its Echopulse systems and the associated consumables required for treatment procedures. The company also earns income from service contracts, maintenance, and training for healthcare profe...
Theraclion SA Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22M | 830.00K | 1.82M | 1.24M | 1.48M | 744.00K |
| Gross Profit | -6.98M | -7.18M | -1.08M | -3.05M | -4.54M | -3.81M |
| EBITDA | -5.66M | -6.96M | -4.49M | -5.74M | -4.40M | -4.15M |
| Net Income | -5.93M | -5.76M | -3.68M | -4.96M | -3.76M | -3.90M |
Balance Sheet | ||||||
| Total Assets | 11.55M | 11.47M | 18.66M | 13.94M | 11.83M | 10.55M |
| Cash, Cash Equivalents and Short-Term Investments | 3.35M | 4.17M | 7.82M | 2.52M | 2.49M | 2.35M |
| Total Debt | 4.30M | 1.30M | 1.95M | 2.51M | 2.39M | 10.61M |
| Total Liabilities | 14.09M | 11.47M | 13.01M | 13.40M | 13.10M | 13.78M |
| Stockholders Equity | -2.54M | -114.00 | 5.65M | 544.87K | -1.27M | -3.24M |
Cash Flow | ||||||
| Free Cash Flow | -5.23M | -3.01M | -2.60M | -5.59M | -4.03M | -3.45M |
| Operating Cash Flow | -4.96M | -2.91M | -2.48M | -5.27M | -3.88M | -3.32M |
| Investing Cash Flow | -295.62K | -188.00K | -213.52K | -739.63K | -524.46K | -192.55K |
| Financing Cash Flow | 2.72M | -545.00K | 7.99M | 6.03M | 4.56M | 4.41M |
Theraclion SA Technical Analysis
Negative
0.61
Price Trends
0.59
Negative
0.61
Negative
0.61
Negative
Market Momentum
-0.04
Positive
38.42
Neutral
34.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHE, the sentiment is Negative. The current price of 0.61 is above the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.59, and below the 200-day MA of 0.61, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 34.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTHE.
Theraclion SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALTHE
Theraclion SA
0.46
0.30
183.33%
GB:0P5I
MAUNA KEA TECHNOLOGIES
0.18
0.10
130.00%
DE:DMS1
Diagnostic Medical Systems
1.17
0.38
48.98%
DE:9W8
Ikonisys SA
1.34
-0.06
-4.30%
DE:4ZG
Median Technologies
4.38
1.92
78.41%
DE:IM11
Implanet SA
0.20
0.12
150.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.